Details

Autor(en) / Beteiligte

• Benemei, Silvia
• Lupi, Chiara
• De Cesaris, Francesco
• Lombardi, Niccolò
• Bettiol, Alessandra
• Chiarugi, Alberto
• Geppetti, Pierangelo
• Galli, Valentina
• Pracucci, Chiara
• Occupati, Brunella
• Mannaioni, Guido

Titel

Low-dose methadone for refractory chronic migraine accompanied by medication-overuse headache: a prospective cohort study

Ist Teil von

• Neurological sciences, 2021-03, Vol.42 (3), p.987-994

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Objectives A refractory chronic migraine (RCM) accompanied by medication-overuse headache (MOH) is an extremely disabling disease. Evidence suggests that in selected patients, chronic opioids may be a valuable therapeutic option for RCM. The aim of the present study was to evaluate the effectiveness and safety of prophylaxis with low-dose methadone (LDM) in patients affected by RCM with continuous headache and MOH. Methods A prospective cohort study was performed between May 2012 and November 2015 at the Headache Center and Toxicology Unit of the Careggi University Hospital. Eligible patients were treated with prophylactic LDM and followed up for 12 months. Headache exacerbations, pain intensity, use of rescue medications, and occurrence of adverse drug reactions (ADRs) were recorded. Results Thirty patients (24 females, median age 48 years) were enrolled. Nineteen (63%) patients dropped out, mainly because of early ADRs ( n  = 10), including nausea, vomiting, and constipation. At last available follow-up, LDM was associated with a significant decrease in the number of headache attacks/month (from a median of 45 (interquartile range 30–150) to 16 (5–30), p  < 0.001), in pain intensity (from 8.5 (8–9) to 5 (3–6), p  < 0.001), and in the number of rescue medications consumed per month (from 95 (34–240) to 15 (3–28), p  < 0.001). No misuse or diversion cases were observed. Conclusion LDM could represent a valuable and effective option in selected patients affected by RCM with continuous headache and MOH, although the frequency of early ADRs poses major safety concerns. Randomized controlled trials are needed to confirm the efficacy and safety of LDM prophylaxis.